Cost-effectiveness analysis of the treatment of mild and moderate Alzheimer’s disease in Brazil
AUTOR(ES)
da Silva, Luciana R., Vianna, Cid M.M., Mosegui, Gabriela B.G., Peregrino, Antônio A.F., Marinho, Valeska, Laks, Jerson
FONTE
Braz. J. Psychiatry.
DATA DE PUBLICAÇÃO
08/11/2018
RESUMO
Objective: To perform a cost-effectiveness analysis of donepezil and rivastigmine therapy for mild and moderate Alzheimer’s disease (AD) from the perspective of the Brazilian Unified Health System. Method: A hypothetical cohort of 1,000 individuals of both sexes, aged >65 years, and diagnosed with AD was simulated using a Markov model. The time horizon was 10 years, with 1-year cycles. A deterministic and probabilistic sensitivity analysis was performed. Results: For mild AD, the study showed an increase in quality-adjusted life years (QALYs) of 0.61 QALY/21,907.38 Brazilian reais (BRL) for patients treated with donepezil and 0.58 QALY/BRL 24,683.33 for patients treated with rivastigmine. In the moderate AD group, QALY increases of 0.05/BRL 27,414.96 were observed for patients treated with donepezil and 0.06/BRL 34,222.96 for patients treated with rivastigmine. Conclusions: The findings of this study contradict the standard of care for mild and moderate AD in Brazil, which is based on rivastigmine. A pharmacological treatment option based on current Brazilian clinical practice guidelines for AD suggests that rivastigmine is less cost-effective (0.39 QALY/BRL 32,685.77) than donepezil. Probabilistic analysis indicates that donepezil is the most cost-effective treatment for mild and moderate AD.
Documentos Relacionados
- Cost-effectiveness of inpatient substance abuse treatment.
- The probability of cost-effectiveness
- Costs of health care: Benefit/Cost and Cost-Effectiveness Analysis
- Cost-effectiveness analysis of diagnostic-therapeutic strategies for visceral leishmaniasis in Brazil
- Erratum: Cyclosporine versus tacrolimus: cost-effectiveness analysis for renal transplantation in Brazil